MedPath

Nafamostat

Generic Name
Nafamostat
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C19H17N5O2
CAS Number
81525-10-2
Unique Ingredient Identifier
Y25LQ0H97D
Background

Nafamostat is a synthetic serine protease inhibitor that is commonly formulated with hydrochloric acid due to its basic properties. It has been used in trials studying the prevention of Liver Transplantation and Postreperfusion Syndrome. The use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing continuous renal replacement therapy due to acute kidney injury.

Indication

Used as an anticoagulant in patients with disseminative blood vessel coagulation, hemorrhagic lesions, and hemorrhagic tendencies. It prevents blood clot formation during extracorporeal circulation in patients undergoing continuous renal replacement therapy and extra corporeal membrane oxygenation.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News
newswire.com
·

Ensysce Biosciences Issues Annual Shareholder Letter

Ensysce Biosciences advanced its TAAP™ and MPAR® platforms in 2024, focusing on PF614 and PF614-MPAR for opioid pain relief with reduced abuse potential. Achieved FDA Breakthrough Therapy designation for PF614-MPAR, progressed clinical trials, and secured $14M NIH grant. Plans include Phase 3 study initiation in 2025 and NDA submission for PF614 by 2026.
ir.ensysce.com
·

Ensysce Biosciences, Inc. Develops Innovative Pain Relief Solutions to Reduce Opioid Misuse and Overdose Risks

Ensysce Biosciences develops innovative pain relief solutions to reduce opioid misuse and overdose risks, featuring the TAAP and MPAR™ platforms. TAAP aims to improve chronic pain care and reduce abuse costs, while MPAR™, combined with TAAP, prevents abuse and overdoses. Nafamostat, used in overdose protection products, is also developed for treating infections and lung diseases.
gurufocus.com
·

Ensysce Biosciences Announces Commercial Supplier for Breakthrou

Ensysce Biosciences secures GMP nafamostat supply for PF614-MPAR, accelerating clinical development and pipeline expansion with Aurore Life Sciences.
morningstar.com
·

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose ...

Ensysce Biosciences secures GMP nafamostat supply for PF614-MPAR, ensuring supply chain security and accelerating clinical development.
stocktitan.net
·

Ensysce Biosciences Secures Critical Supply Deal for Breakthrough Overdose Protection

Ensysce Biosciences secured future supply of GMP nafamostat from Aurore Life Sciences for PF614-MPAR, its overdose protection drug product, ensuring the supply chain and allowing reference to Aurore's Drug Master File. This agreement also benefits other nafamostat-based programs.
finance.yahoo.com
·

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

Ensysce Biosciences secures GMP nafamostat supply from Aurore Life Sciences for PF614-MPAR, enhancing overdose protection and advancing clinical development. This partnership supports Ensysce's innovative pain relief solutions aimed at reducing opioid abuse and overdose risks.
biospace.com
·

Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in ...

Ensysce Biosciences treated first group in PF614-MPAR-102 study, aiming for early interim data in 1Q 2025. PF614-MPAR received FDA Breakthrough Therapy designation, supported by a $14 million NIDA award. Ensysce targets reducing opioid abuse and overdose with its TAAP and MPAR platforms.
stocktitan.net
·

Ensysce Biosciences Launches Key Trial for Breakthrough Opioid Drug, Backed by $14M NIDA Grant

Ensysce Biosciences initiates dosing in PF614-MPAR-102 study, evaluating oxycodone and PF614 pharmacokinetics with nafamostat, funded by a $14 million NIDA award, with interim data expected in Q1 2025.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy